Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension

Sacubitril/valsartan (LCZ696) is indicated for the treatment of patients with heart failure and reduced ejection fraction (HFrEF). Since patients with HFrEF may receive sacubitril/valsartan and sildenafil, both increasing cyclic guanosine monophosphate, the present study evaluated the pharmacokineti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiao, H‐L, Langenickel, TH, Petruck, J, Kode, K, Ayalasomayajula, S, Schuehly, U, Greeley, M, Pal, P, Zhou, W, Prescott, MF, Sunkara, G, Rajman, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836847/
https://www.ncbi.nlm.nih.gov/pubmed/28599060
http://dx.doi.org/10.1002/cpt.759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836847/
https://www.ncbi.nlm.nih.gov/pubmed/28599060
http://dx.doi.org/10.1002/cpt.759

Ejemplares similares